Literature DB >> 10073742

Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.

R F Schäfers1, B Fokuhl, A Wasmuth, H Schumacher, K Taguchi, C de Mey, T Philipp, M C Michel.   

Abstract

AIMS: In patients with lower urinary tract symptoms suggestive of benign prostatic obstruction the alpha1-adrenoceptor antagonist terazosin lowers blood pressure whereas only very small if any alterations were reported with the alpha1-adrenoceptor antagonist tamsulosin. Therefore, we have compared the vascular alpha1-adrenoceptor antagonism of tamsulosin and terazosin directly.
METHODS: Ten healthy subjects were investigated in a randomized, single-blind, three-way cross-over design and received a single dose of 0.4 mg tamsulosin, 5 mg terazosin or placebo on 3 study days at least 1 week apart. Before and 1, 3, 5, 7, 10 and 23.5 h after drug intake, alterations of diastolic blood pressure and other haemodynamic parameters in response to a graded infusion of the alpha1-adrenoceptor agonist phenylephrine were determined non-invasively.
RESULTS: At most time points tamsulosin inhibited phenylephrine-induced diastolic blood pressure elevations significantly less than terazosin (5 h time point: median difference in inhibition 35%, 95% CI: 18.7-50.3%). On the other hand, phenylephrine-induced changes of cardiac output, heart rate and stroke volume were similar during both active treatments.
CONCLUSIONS: In doses equi-effective for treatment of lower urinary tract symptoms tamsulosin causes less inhibition of vasoconstriction than terazosin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073742      PMCID: PMC2014197          DOI: 10.1046/j.1365-2125.1999.00856.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  34 in total

1.  An evaluation of the alpha-adrenoceptor antagonism produced by SK&F 86466 in healthy normotensive males.

Authors:  R F Schafers; H L Elliott; C A Howie; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

2.  Development and evaluation of an impedance cardiac output system.

Authors:  W G Kubicek; J N Karnegis; R P Patterson; D A Witsoe; R H Mattson
Journal:  Aerosp Med       Date:  1966-12

3.  Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects.

Authors:  R F Schafers; H L Elliott; C A Howie; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

4.  Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?

Authors:  M C Michel; L Mehlburger; H U Bressel; H Schumacher; R F Schäfers; M Goepel
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

5.  Terazosin kinetics after oral and intravenous doses.

Authors:  S E Patterson
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.

Authors:  M K Brawer; G Adams; H Epstein
Journal:  Arch Fam Med       Date:  1993-09

7.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

Authors:  H Lepor; S Auerbach; A Puras-Baez; P Narayan; M Soloway; F Lowe; T Moon; G Leifer; P Madsen
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

8.  Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.

Authors:  A Hatano; H Takahashi; M Tamaki; T Komeyama; T Koizumi; M Takeda
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  Characterization of alpha 1-adrenoceptors mediating vasoconstriction to noradrenaline and nerve stimulation in the isolated perfused mesentery of rat.

Authors:  T J Williams; D E Clarke
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

10.  Pharmacokinetics of terazosin.

Authors:  R C Sonders
Journal:  Am J Med       Date:  1986-05-23       Impact factor: 4.965

View more
  4 in total

1.  Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?

Authors:  Cees Korstanje; Walter Krauwinkel; Francisca L C van Doesum-Wolters
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 2.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  A 6-month large-scale study into the safety of tamsulosin.

Authors:  M C Michel; H U Bressel; M Goepel; H Rübben
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 4.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.